ORLANDO, Fla., Dec. 13, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Immune Therapeutics, Inc. (OTCQB:IMUN) ("Immune" “IMUN” or the "Company"), a clinical late stage biopharmaceutical company focused on the development of therapies for the treatment of autoimmune diseases, inflammatory diseases, cancer and HIV/AIDS announced today that their lead therapy, Lodonal™  (LDN), was featured in an article published in A&U Magazine (https://issuu.com/aumagazine/docs/a_u_december2018 pg. 59).

The article, titled “The Next Waltz,” cited studies suggesting Lodonal’s potential for changing the course of the epidemic by treating HIV-related comorbidities driven by inflammation such as Chron’s disease, inflammatory bowel disease (IBD), and irritable bowel syndrome (IBS).  Addressing that, “existing medications to treat inflammatory bowel diseases (IBD), such as Crohn’s disease and irritable bowel syndrome (IBS), can cause significant immune suppression which can be more damaging in PLWHAs than those with IBD alone.” The author goes on to say; “Lodonal is hopefully the first in a line of new therapies needed for people living with HIV and Crohn’s or IBS.”  The comprehensive article also shows studies suggesting Lodonal™ and LDN ’s potential “…to enhance the immune system,” demonstrating “…CD4 recovery that was attributed to decreases in inflammatory cytokines.”

Another study mentioned, from the University of Minnesota, discovered that “Naltrexone affected HIV expression in CD4 lymphocyte cultures which play a role in the potentiation of antiretroviral drugs and suggest that clinical trials should be considered of naltrexone as an adjunctive therapy of HIV infection.”  Dr. David Malebranche Associate Professor at the Moorehouse School of Medicine, is quoted in article saying that “Naltrexone would be a good intervention option for HIV-positive people.” and points out that, “As a medical and research community we focus on interventions such as bnAbs [broadly neutralizing antibodies], two drug regimens, vaccines, etc., and forget about intersecting epidemics.”

The author surmised that: “Separately, and collectively, these studies indicate that Naltrexone, in its various forms,” (Lodonal™ /LDN) “…is a unique and versatile therapy that holds potential for several uses in HIV disease and other conditions. PLWHAs struggling to recover immune function and those addicted to opiates and alcohol may strongly benefit from its use and guidelines to assist these key populations of PLWHAs should be considered to help maintain viral suppression and treatment retention.”

Following the next few press releases, Immune Therapeutics, Inc. intends to make future announcements regarding its financial and corporate performance exclusively through its website and Facebook page.  Website: https://www.immunetherapeutics.com/
Facebook:  https://www.facebook.com/ImmuneTherapeutics/
An upcoming press release will detail the date of this transition.

About A&U
A&U Magazine is a monthly direct to consumer magazine focused on issues relating to HIV, including HIV research, policy, treatment and prevention. A&U Magazine was founded in 1991 and is distributed through direct mail and at AIDS service organizations, doctor’s offices, and HIV clinics across the United States. A&U Magazine is also available online.

Immune Therapeutics Inc. is a late stage clinical stage biopharmaceutical company focused on the development and commercialization of our highly innovative immunotherapies. IMUN is a biotechnology company developing T-Activation immunotherapies to achieve immunomodulation in patients with autoimmune and inflammatory disease and cancer and infectious diseases.

Forward-Looking Statements
This release may contain forward-looking statements. Actual results may differ from those projected due to a number of risks and uncertainties, including, but not limited to, the possibility that some or all the matters and transactions considered by the Company may not proceed as contemplated, and by all other matters specified in the Company’s filings with the Securities and Exchange Commission. These statements are made based upon current expectations that are subject to risk and uncertainty. The Company does not undertake to update forward-looking statements in this news release to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking information. Assumptions and other information that could cause results to differ from those set forth in the forward-looking information can be found in the Company’s filings with the Securities and Exchange Commission (www.sec.gov), including its recent periodic reports.